Supplementary Tables – Infection rates and tolerability of three different immunoglobulin administration modalities in patients with PID
datasetposted on 2021-12-21, 14:52 authored by Figshare Future Science GroupFigshare Future Science Group, Richard L. Wasserman, Sudhir Gupta, Mark Stein, Christopher J. Rabbat, Werner Engl, Heinz Leibl, Leman Yel
Supplemental Table 1. Participant demographics and baseline characteristics.
Supplemental Table 2. Annualized rates of infections by IgG route of administration for subgroup of participants sequentially treated with IVIG, SCIG, and fSCIG and total population from clinical studies.
Supplemental Table 3. IgG peak and trough levels by infusion interval.
Supplemental Table 4. Causally related AEs (excluding infections).
Supplemental Table 5. Causally related AEs (excluding infections) by IgG route of administration for subgroup of participants sequentially treated with IVIG, SCIG, and fSCIG and total population from clinical studies.
Baxalta US Inc., a Takeda company
Read the peer-reviewed publication
Facilitated subcutaneous immunoglobulinfSCIGimmunoglobulin Gphase 3primary immunodeficiency diseasesPIDsubcutaneous immunoglobulinSCIGintravenous immunoglobulinIVIGImmunogenetics (incl. Genetic Immunology)Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)Immunology not elsewhere classified